• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Retinal assessment made easy by digital imaging

Article

Wakeforest, NC-Digital Healthcare Inc. has received FDA approval to pre-market its retinal risk assessment system (Retasure) and its iP technology platform.

Wakeforest, NC-Digital Healthcare Inc. has received FDA approval to pre-market its retinal risk assessment system (Retasure) and its iP technology platform.

Primary-care physicians now can capture digital images of diabetic patients' retinas in a non-invasive procedure. The digital images are transmitted over a secure, HIPPA-compliant network to a board-certified ophthalmologist at an accredited reading center for examination and assessment.

Seven major contracts with primary diabetes care and ophthalmology providers have already been announced, and general availability throughout the United States is being planned.

This system is unique because it can be operated by non-clinicians; it's non-invasive and requires no dilation; it obtains high-quality digital images of the retina; it returns results quickly to primary-care physicians; and it encourages patient compliance for regular retinal assessment, according to Digital Healthcare.

Related Videos
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.